|Awarded On||August 24, 2018|
|Title||Predictive Biomarkers and Novel Therapies for High-Risk Pediatric Liver Cancers|
|Award Mechanism||Multi-Investigator Research Awards (Version 2)|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Dolores Lopez-Terrada|
|Cancer Sites||Gallbladder, Liver and Intrahepatic Bile Duct|
Hepatoblastoma (HB) and hepatocellular carcinoma (HCC) are the two most frequently diagnosed liver cancers in children. These cancers can be divided into smaller groups based on the look of the cells under the microscope and their molecular programming. Depending on which type of HB or HCC a child has, the prognosis can vary: some children with “low-risk” HBs are cured by surgical removal of the tumor, some children require additional chemotherapy while children with “high-risk” HBs and HCCs continue to have a dismal prognosis of 30-50% at 5 years despite maximal medical and surgical therapy. Treatments for these tumors include surgical resection or liver transplantation in combination with ...